The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while maintaining a comparable safety profile.